The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Lung Cancer Diagnostics-Global Market Insights and Sales Trends 2024
Synopsis
Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
The global Lung Cancer Diagnostics market size is expected to reach US$ 2783 million by 2029, growing at a CAGR of 5.7% from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Diagnostics in various end use industries. The expanding demands from the Industrial, Healthcare and Other,, are propelling Lung Cancer Diagnostics market. Immunoassays, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Flow Cytometry segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Diagnostics covered in this report include Roche Diagnostics, BioMérieux, Qiagen, Advpharma, AIT Austrian Institute of Technology, Courtagen Life Sciences, DiagnoCure, BioMark Diagnostics and Mayo Clinic, etc.
The global Lung Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Diagnostics
BioMérieux
Qiagen
Advpharma
AIT Austrian Institute of Technology
Courtagen Life Sciences
DiagnoCure
BioMark Diagnostics
Mayo Clinic
HalioDx SAS
Global Lung Cancer Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Diagnostics market, Segment by Type:
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other
Global Lung Cancer Diagnostics market, by Application
Industrial
Healthcare
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
The global Lung Cancer Diagnostics market size is expected to reach US$ 2783 million by 2029, growing at a CAGR of 5.7% from 2023 to 2029. The market is mainly driven by the significant applications of Lung Cancer Diagnostics in various end use industries. The expanding demands from the Industrial, Healthcare and Other,, are propelling Lung Cancer Diagnostics market. Immunoassays, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Flow Cytometry segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lung Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lung Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lung Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lung Cancer Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lung Cancer Diagnostics covered in this report include Roche Diagnostics, BioMérieux, Qiagen, Advpharma, AIT Austrian Institute of Technology, Courtagen Life Sciences, DiagnoCure, BioMark Diagnostics and Mayo Clinic, etc.
The global Lung Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Diagnostics
BioMérieux
Qiagen
Advpharma
AIT Austrian Institute of Technology
Courtagen Life Sciences
DiagnoCure
BioMark Diagnostics
Mayo Clinic
HalioDx SAS
Global Lung Cancer Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lung Cancer Diagnostics market, Segment by Type:
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other
Global Lung Cancer Diagnostics market, by Application
Industrial
Healthcare
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lung Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Lung Cancer Diagnostics
1.1 Lung Cancer Diagnostics Market Overview
1.1.1 Lung Cancer Diagnostics Product Scope
1.1.2 Lung Cancer Diagnostics Market Status and Outlook
1.2 Global Lung Cancer Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Lung Cancer Diagnostics Market Size by Region (2018-2029)
1.4 Global Lung Cancer Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Lung Cancer Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Lung Cancer Diagnostics Market Size (2018-2029)
1.6.1 North America Lung Cancer Diagnostics Market Size (2018-2029)
1.6.2 Europe Lung Cancer Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Lung Cancer Diagnostics Market Size (2018-2029)
1.6.4 Latin America Lung Cancer Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Lung Cancer Diagnostics Market Size (2018-2029)
2 Lung Cancer Diagnostics Market by Type
2.1 Introduction
2.1.1 Immunoassays
2.1.2 Flow Cytometry
2.1.3 Rapid Tests
2.1.4 Molecular Assays
2.1.5 Tissue Arrays
2.1.6 Circulating Tumor Cells
2.1.7 Pharmacodiagnostics
2.1.8 Biomarkers
2.1.9 Other
2.2 Global Lung Cancer Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Lung Cancer Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Lung Cancer Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Lung Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Lung Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Lung Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Lung Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Lung Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
3 Lung Cancer Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Industrial
3.1.2 Healthcare
3.1.3 Other
3.2 Global Lung Cancer Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Lung Cancer Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Lung Cancer Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Lung Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Lung Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Lung Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Lung Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Lung Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
4 Lung Cancer Diagnostics Competition Analysis by Players
4.1 Global Lung Cancer Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lung Cancer Diagnostics as of 2022)
4.3 Date of Key Players Enter into Lung Cancer Diagnostics Market
4.4 Global Top Players Lung Cancer Diagnostics Headquarters and Area Served
4.5 Key Players Lung Cancer Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Lung Cancer Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche Diagnostics
5.1.1 Roche Diagnostics Profile
5.1.2 Roche Diagnostics Main Business
5.1.3 Roche Diagnostics Lung Cancer Diagnostics Products, Services and Solutions
5.1.4 Roche Diagnostics Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Diagnostics Recent Developments
5.2 BioMérieux
5.2.1 BioMérieux Profile
5.2.2 BioMérieux Main Business
5.2.3 BioMérieux Lung Cancer Diagnostics Products, Services and Solutions
5.2.4 BioMérieux Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 BioMérieux Recent Developments
5.3 Qiagen
5.3.1 Qiagen Profile
5.3.2 Qiagen Main Business
5.3.3 Qiagen Lung Cancer Diagnostics Products, Services and Solutions
5.3.4 Qiagen Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Advpharma Recent Developments
5.4 Advpharma
5.4.1 Advpharma Profile
5.4.2 Advpharma Main Business
5.4.3 Advpharma Lung Cancer Diagnostics Products, Services and Solutions
5.4.4 Advpharma Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Advpharma Recent Developments
5.5 AIT Austrian Institute of Technology
5.5.1 AIT Austrian Institute of Technology Profile
5.5.2 AIT Austrian Institute of Technology Main Business
5.5.3 AIT Austrian Institute of Technology Lung Cancer Diagnostics Products, Services and Solutions
5.5.4 AIT Austrian Institute of Technology Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 AIT Austrian Institute of Technology Recent Developments
5.6 Courtagen Life Sciences
5.6.1 Courtagen Life Sciences Profile
5.6.2 Courtagen Life Sciences Main Business
5.6.3 Courtagen Life Sciences Lung Cancer Diagnostics Products, Services and Solutions
5.6.4 Courtagen Life Sciences Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 Courtagen Life Sciences Recent Developments
5.7 DiagnoCure
5.7.1 DiagnoCure Profile
5.7.2 DiagnoCure Main Business
5.7.3 DiagnoCure Lung Cancer Diagnostics Products, Services and Solutions
5.7.4 DiagnoCure Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 DiagnoCure Recent Developments
5.8 BioMark Diagnostics
5.8.1 BioMark Diagnostics Profile
5.8.2 BioMark Diagnostics Main Business
5.8.3 BioMark Diagnostics Lung Cancer Diagnostics Products, Services and Solutions
5.8.4 BioMark Diagnostics Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 BioMark Diagnostics Recent Developments
5.9 Mayo Clinic
5.9.1 Mayo Clinic Profile
5.9.2 Mayo Clinic Main Business
5.9.3 Mayo Clinic Lung Cancer Diagnostics Products, Services and Solutions
5.9.4 Mayo Clinic Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 Mayo Clinic Recent Developments
5.10 HalioDx SAS
5.10.1 HalioDx SAS Profile
5.10.2 HalioDx SAS Main Business
5.10.3 HalioDx SAS Lung Cancer Diagnostics Products, Services and Solutions
5.10.4 HalioDx SAS Lung Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 HalioDx SAS Recent Developments
6 North America
6.1 North America Lung Cancer Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Lung Cancer Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Lung Cancer Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Lung Cancer Diagnostics Market Dynamics
11.1 Lung Cancer Diagnostics Industry Trends
11.2 Lung Cancer Diagnostics Market Drivers
11.3 Lung Cancer Diagnostics Market Challenges
11.4 Lung Cancer Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
